John S Tokarski

US Patent:

6653304, Nov 25, 2003

Filed:

Feb 8, 2001

Appl. No.:

09/779109

Inventors:

Katerina Leftheris - Skillman NJ
Hong Wu - Lawrenceville NJ
Stephen Wrobleski - Whitehouse Station NJ
Ping Chen - Belle Mead NJ
John Hynes - Washington Crossing PA
John Tokarski - Princeton NJ

Assignee:

Bristol-Myers Squibb Co. - Princeton NJ

International Classification:

C07D40312

US Classification:

5142328, 514292, 544126, 546 81

Abstract:

Use of a compound for treating a respiratory disease in a mammal wherein the compound is a cannabinoid receptor modulator is disclosed. Compounds useful as cannabinoid receptor modulators for treating respiratory and non-respiratory leukocyte-activation associated diseases comprise compounds of formula (I), in which A and B are nitrogen or carbon, provided only one of A and B is nitrogen; and R -R are as defined in the specification, wherein R with R may form a ring, and/or two R groups may form a six-membered aryl or heteroaryl ring, optionally having a substituent R forming a ring with R.

US Patent:

7723336, May 25, 2010

Filed:

Mar 21, 2007

Appl. No.:

11/689132

Inventors:

Wayne Vaccaro - Yardley PA,
Zhong Chen - Princeton NJ,
Dharmpal S. Dodd - Princeton NJ,
Tram N. Huynh - Pennington NJ,
James Lin - Lawrenceville NJ,
Chunjian Liu - Pennington NJ,
Christopher P. Mussari - Princeton NJ,
John S. Tokarski - Princeton NJ,
David R. Tortolani - Skillman NJ,
Stephen T. Wrobleski - Whitehouse Station NJ,
Shuqun Lin - Newtown PA,

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
A61K 31/5025
A61P 19/02

US Classification:

514248, 544236

Abstract:

Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof,.

US Patent:

20140005146, Jan 2, 2014

Filed:

Mar 16, 2012

Appl. No.:

14/005572

Inventors:

Stephen T. Wrobleski - Flemington NJ,
Jagabandhu Das - Mercerville NJ,
Lidia M. Doweyko - Vero Beach FL,
Junqing Guo - Princeton NJ,
John Hynes - Washington Crossing PA,
Bin Jiang - Norristown PA,
James Kempson - Princeton NJ,
Shuqun Lin - Newtown PA,
Steven H. Spergel - Warrington PA,
John S. Tokarski - Princeton NJ,
Hong Wu - New Hope PA,
Bingwei Vera Yang - Belle Mead NJ,

International Classification:

C07D 487/04
C07F 9/6561

US Classification:

514 80, 5142308, 544119, 514248, 544235, 540200, 51421002, 5142285, 544 582, 5142332, 544232

Abstract:

Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

US Patent:

20110039838, Feb 17, 2011

Filed:

Oct 25, 2010

Appl. No.:

12/911299

Inventors:

Brian E. Fink - Yardley PA,
Ashvinikumar V. Gavai - Princeton Junction NJ,
Gregory D. Vite - Titusville NJ,
Ping Chen - Belle Mead NJ,
Harold Mastalerz - Guilford CT,
Derek J. Norris - Pennington NJ,
John S. Tokarski - Princeton NJ,
Yufen Zhao - Pennington NJ,
Wen-Ching Han - Newtown PA,

International Classification:

A61K 31/53
C07D 487/04
A61K 31/5377
C07D 498/04
A61K 31/5383
A61P 35/00
A61P 17/06
A61P 29/00
G01N 33/53

US Classification:

5142305, 544183, 514243, 544112, 5142332, 544105, 435 771

Abstract:

The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

US Patent:

20100029676, Feb 4, 2010

Filed:

Nov 3, 2006

Appl. No.:

12/092360

Inventors:

Charles L. Sawyers - Los Angeles CA,
Michael Burgess - Los Angeles CA,
Neil Pravin Shah - Los Angeles CA,
Francis Y. Lee - Yardley PA,
John S. Tokarski - Princeton NJ,
Herbert E. Klei - Lawrenceville NJ,

International Classification:

A61K 31/497
C12Q 1/48
G01N 33/53
C12Q 1/68

US Classification:

51425219, 435 15, 435 71, 435 6

Abstract:

The present invention relates to mutant BCR-ABL kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant BCR-ABL kinase proteins.

US Patent:

20070078136, Apr 5, 2007

Filed:

Sep 21, 2006

Appl. No.:

11/524996

Inventors:

Wayne Vaccaro - Yardley PA,
Zhong Chen - Princeton NJ,
Dharmpal Dodd - Princeton NJ,
Tram Huynh - Pennington NJ,
James Lin - Lawrenceville NJ,
Chunjian Liu - Pennington NJ,
Christopher Mussari - Princeton NJ,
John Tokarski - Princeton NJ,
David Tortolani - Skillman NJ,
Stephen Wrobleski - Whitehouse Station NJ,

International Classification:

C07D 487/04
A61K 31/53
A61K 31/503

US Classification:

514243000, 514246000, 514248000, 544184000, 544235000

Abstract:

Compounds having the formula (1), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are usefuil as kinase modulators, including MK2 modulation, wherein one of E and F is a nitrogen atom and the other of E and F is a carbon atom, Z is N or CR, and R, R, R, X and Y are as defined herein.

US Patent:

7880004, Feb 1, 2011

Filed:

Sep 14, 2006

Appl. No.:

11/521035

Inventors:

Robert M. Borzilleri - New Hope PA,
Donna D. Wei - Belle Mead NJ,
John S. Tokarski - Princeton NJ,

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/444
A61K 31/437
C07D 471/04
C07D 213/64

US Classification:

546113, 546261, 514300, 514335

Abstract:

The invention is directed to compounds that are useful for the treatment of cancer having the following Formula:.

US Patent:

7846931, Dec 7, 2010

Filed:

Sep 24, 2008

Appl. No.:

11/869910

Inventors:

Brian E. Fink - Princeton Junction NJ,
Ashvinikumar V. Gavai - Princeton Junction NJ,
Gregory D. Vite - Titusville NJ,
Ping Chen - Belle Mead NJ,
Harold Mastalerz - Guilford CT,
Derek J. Norris - Pennington NJ,
John S. Tokarski - Princeton NJ,
Yufen Zhao - Pennington NJ,
Wen-Ching Han - Newtown PA,

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/53
A61P 35/00
C07D 401/06
C07D 401/14

US Classification:

514243, 544183

Abstract:

The present invention provides compounds of formula IThe formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.